Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-04-27 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the revision of the company's Articles of Association (公司章程). It details specific amendments to the company's governance documents, including changes to shareholder meeting procedures, board responsibilities, and other governance-related provisions. The document is a formal announcement of proposed changes to the company's governance structure and bylaws, intended to be submitted for shareholder approval. It does not contain financial statements, audit results, or detailed financial performance data. It is not a full annual report, interim report, or earnings release. Nor is it a proxy solicitation or voting results announcement. The content focuses on governance structure and company bylaws, which fits the category of Governance Information (CGR). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it contains substantive governance content. Therefore, the appropriate classification is Governance Information (CGR).
2023-04-27 Chinese
昆药集团2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年第一季度报告" which translates to "2023 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the first quarter of 2023. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements, management discussion on business performance, shareholder information, and notes on significant events during the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese
昆药集团关于变更会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Corporation regarding the change of its auditing firm from Ernst & Young Hua Ming to KPMG Huazhen for the 2023 fiscal year. It details the background, qualifications, and independence of the new auditor, the communication with the previous auditor, and the approval process including board and independent directors' opinions. The document does not contain any financial statements or audit reports themselves but is a formal announcement about the change of auditor and the upcoming shareholder meeting to approve this change. The document length is under 5,000 characters and it serves as a regulatory announcement rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates specifically to audit firm change and audit-related information, not a full annual report or other categories. FY 2023
2023-04-27 Chinese
昆药集团独立董事关于公司十届十五次董事会相关事项的事前认可及独立意见
Audit Report / Information Classification · 95% confidence The document contains independent directors' opinions regarding board meeting matters, specifically about changing the company's accounting firm and asset impairment provisions. It references compliance with governance rules and regulations but does not include financial statements or detailed audit results. The document is a formal opinion or approval related to board decisions, not the audit report itself. Given the focus on audit firm change and related board opinions, this fits best under Audit Report / Information (AR), which includes audit-related reports and opinions excluding full annual reports. The document length is short and does not present full financial data, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive independent directors' opinions rather than just an announcement. Therefore, the classification is AR with high confidence. FY 2023
2023-04-27 Chinese
昆药集团股份有限公司章程
Governance Information Classification · 100% confidence The document is titled "昆药集团股份有限公司章程" which translates to "Articles of Association of KPC Pharmaceuticals, Inc." It is a detailed corporate governance document outlining the company's organizational structure, shareholder rights, board and management roles, financial accounting systems, profit distribution, audit, and other governance-related matters. The content includes chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, party committee, board of directors, senior management, supervisory board, financial accounting system, internal audit, appointment of accounting firms, external investment management, labor and personnel system, stakeholders, environmental protection and social responsibility, liabilities, notices and announcements, mergers, capital changes, dissolution and liquidation, amendments to the articles, and supplementary provisions. This document is a governance framework document, not a financial report, earnings release, or announcement. It is not a proxy statement or remuneration report. It is a detailed governance document that defines the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary.
2023-04-27 Chinese
昆药集团十届十五次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kunming Pharmaceutical Group regarding their meeting held on April 27, 2023. It discusses approval of the company's 2023 first quarter report, asset impairment provisions, and a proposal to change the accounting firm. The document does not contain the actual financial statements or detailed financial data but rather the Supervisory Board's opinions and approvals related to these matters. It also references the first quarter report being published on the Shanghai Stock Exchange website, indicating this document is an announcement of supervisory board resolutions rather than the report itself. Given the short length (929 characters) and the nature of the content, this fits best under Regulatory Filings (RNS) as it is a regulatory announcement about supervisory board decisions and approvals, not the full interim report or audit report itself.
2023-04-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.